Celcuity: From Speculative Bet To Pre-Commercial Powerhouse (NASDAQ:CELC)

In February, I covered Celcuity ( CELC ), stating that the stock price was fundamentally discounting its risk/reward ratio. By that time, Celcuity was a speculative play with deep skepticism around the toxicities associated with oral PI3K inhibitorsI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My approach is a mix of fundamenta ...